Author

A. Ritter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Banito· 2 shared E. Vinca· 2 shared F. Cidre-Aranaz· 2 shared F. H. Geyer· 2 shared J. Li· 2 shared R. Imle· 2 shared S. Ohmura· 2 shared T. G. P. Gruenewald· 2 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Banito

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Super-enhancer-driven CACNA2D2 is an EWSR1::WT1 signature gene encoding a diagnostic marker for desmoplastic small round cell tumor (DSRCT)

F. H. Geyer, A. Ritter, S. Kinn-Gurzo, T. Faehling, J. Li, A. Jarosch, C. Ngo, E. Vinca, K. Aljakouch, A. Orynbek, S. Ohmura, T. Kirchner, R. Imle, L. Romero-Perez, S. Bertram, , F. Cidre-Aranaz

The paper identifies CACNA2D2 as a super-enhancer-driven target of EWSR1::WT1 and demonstrates its utility as a diagnostic biomarker for DSRCT.

bioRxiv · Jul 17, 2024 · PreprintCancer Biology

Serum Proteome Profiling Identifies N-Cadherin and C-Met as Early Marker Candidates of Therapeutic Response to Neoadjuvant Chemotherapy in Breast Cancer

I. D. Steenbuck, M. Cosenza-Contreras, K. Froehlich, B. Mayer, K. Kurowski, M. Reinold, M. Fahrner, F. Hause, T. Feilen, A. Seredynsksa, A. Ritter, A. Arnoux, M. L. Biniossek, D. Weiss, C. Noethling, , O. Schilling

bioRxiv · May 24, 2024 · PreprintCancer Biology

Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

E. Vinca, A. C. Ehlers, A. Ritter, D. Obermeier, C. M. Funk, F. H. Geyer, M. Schmucker, J. Li, M. Zimmermann, A. K. Ceranski, F. Fuchslocher, C. Mertens, R. Qiu, M. M. Muckenthaler, A. Dahlhaus, , S. Ohmura

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.

bioRxiv · Apr 24, 2024 · PreprintCancer Biology

Surveillance of in situ tumor arrays reveals early environmental control of cancer immunity

G. Ortiz-Munoz, M. Brown, C. B. Carbone, J. Pechuan Jorge, A. Ritter, D. Orlova, S. R. Mantri, A. Yang, J. Doerr, S. Mariathasan, Y. Wang, S. Turley, C. Gomez-Roca, C. Eduardo de Andrea, D. Spigel, , C. Moussion

This study introduces STAMP, a method to monitor tumor-immune dynamics in vivo, showing immune phenotypes evolve over time and correlate with therapeutic response.

bioRxiv · May 27, 2021 · PreprintCancer Biology